Madrigal Pharmaceuticals beat Q1 sales estimates with Rezdiffra, and catalysts like EU approval and pipeline plans add upside ...

Duffy is the second member of Trump’s cabinet who sold securities shortly before the president’s tariff announcements sent ...

Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an ...

Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

Madrigal Pharmaceuticals markets the only approved therapy for a disease whose prevalence is growing. Investing in promising companies before their stock prices soar is an excellent recipe for ...

DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market size during the study period (2020–2034). This anticipated ...

The most significant addition was Honeywell International Inc (NASDAQ:HON), with 200,000 shares, accounting for 2.42% of the ...

Madrigal Pharmaceuticals aims to roll out REZDIFFRA across Europe starting with Germany in the second half of 2025, pending EMA approval for REZDIFFRA, making it the first authorized therapy for ...